A Dose Escalation and Dose Expansion Trial of WTX212A in the Treatment of Patients with Advanced Malignant Tumors

NCT06026605 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Unresectable or Metastatic Advanced Solid Tumors

Interventions

DRUG: WTX212A

Sponsor

Zhejiang University